首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1521篇
  免费   112篇
  国内免费   2篇
耳鼻咽喉   12篇
儿科学   70篇
妇产科学   35篇
基础医学   209篇
口腔科学   67篇
临床医学   83篇
内科学   335篇
皮肤病学   38篇
神经病学   162篇
特种医学   25篇
外科学   166篇
综合类   7篇
预防医学   119篇
眼科学   47篇
药学   108篇
中国医学   14篇
肿瘤学   138篇
  2023年   11篇
  2022年   25篇
  2021年   61篇
  2020年   24篇
  2019年   39篇
  2018年   40篇
  2017年   40篇
  2016年   48篇
  2015年   45篇
  2014年   60篇
  2013年   74篇
  2012年   117篇
  2011年   115篇
  2010年   71篇
  2009年   66篇
  2008年   96篇
  2007年   89篇
  2006年   91篇
  2005年   90篇
  2004年   73篇
  2003年   46篇
  2002年   59篇
  2001年   24篇
  2000年   17篇
  1999年   22篇
  1998年   10篇
  1997年   4篇
  1996年   10篇
  1995年   9篇
  1994年   6篇
  1993年   6篇
  1992年   18篇
  1991年   11篇
  1990年   7篇
  1989年   5篇
  1988年   6篇
  1987年   7篇
  1986年   7篇
  1985年   11篇
  1984年   6篇
  1983年   6篇
  1982年   4篇
  1976年   8篇
  1975年   5篇
  1973年   5篇
  1972年   5篇
  1970年   5篇
  1967年   4篇
  1966年   6篇
  1965年   4篇
排序方式: 共有1635条查询结果,搜索用时 31 毫秒
971.
Background:To determine the effect of intramuscular administration of Neostigmine® on the visualization of the pancreatic duct on magnetic resonance cholangiopancreatography in patients with recurrent acute pancreatitis or abdominal pain.Methods:We reviewed patients undergoing magnetic resonance cholangiopancreatography followed by a Neostigmine®-enhanced magnetic resonance cholangiopancreatography. Patients with a history of recurrent acute pancreatitis or abdominal pain who had a magnetic resonance cholangiopancreatography where the pancreatic duct was not entirely seen, were selected to undergo a second magnetic resonance cholangiopancreatography 40 minutes after 0.5 mg Neostigmine®. Images were analyzed by 2 radiologists. The diameter of the pancreatic duct was measured in the head, body, and tail of the pancreas on the baseline images and after Neostigmine®.Results:Ten patients were included, with a median age of 33 years (range 15-61). The maximum diameter of the pancreatic duct increased significantly after Neostigmine® administration in all patients, from 1.84 ± 0.98 to 3.41 ± 1.27 mm in the head, 1.34 ± 0.42 mm to 2.5 ± 0.49 mm in the body and 0.72 ± 0.52 mm to 1.78 ± 0.43 mm in the tail (mean ± SD, P < .0001). Neostigmine® helped to provide better detail of the pancreatic duct anatomy in 4 patients. In 2 patients we confirmed pancreas divisum, in another the Santorini duct was not seen on the baseline images but it was clearly visualized after Neostigmine®, and in the fourth patient, Neostigmine® improved visualization of multiple pancreatic duct stenosis.Conclusion:Neostigmine®-magnetic resonance cholangiopancreatography significantly increases the diameter of the pancreatic duct, allowing an accurate morphological evaluation. It could be a cheap alternative to secretin, which is expensive and hardly available.  相似文献   
972.
The prognosis of advanced pancreatic adenocarcinoma is still extremely poor. This study sought to determine the efficacy of, and immunological response to, peptide vaccination therapy in patients with this disease. In this multicenter randomized phase II study, patients with advanced pancreatic adenocarcinoma after gemcitabine and/or tegafur/gimeracil/oteracil were randomly assigned to 3 groups that each received a 2‐step treatment course. In Step 1, the groups received treatments of: (i) survivin 2B peptide (SVN‐2B) plus interferon‐β (IFNβ); (ii) SVN‐2B only; or (iii) placebo until the patients show progression. In Step 2, all patients who consented to participate received 4 treatments with SVN‐2B plus IFNβ. The primary endpoint was progression‐free survival (PFS) after initiation of Step 1 treatment. Secondary endpoints included immunological effects assessed by analysis of PBMCs after Step 1. Eighty‐three patients were randomly assigned to receive SVN‐2B plus IFNβ (n = 30), SVN‐2B (n = 34), or placebo (n = 19). No significant improvement in PFS was observed. Survivin 2B‐specific CTLs were found to be increased in the SVN‐2B plus IFNβ group by tetramer assay. Among patients who participated in Step 2, those who had received SVN‐2B plus IFNβ in Step 1 showed better overall survival compared with those who had received placebo in Step 1. Patients vaccinated with SVN‐2B plus IFNβ did not have improved PFS, but showed significant immunological reaction after vaccination. Subgroup analysis suggested that a longer SVN‐2B plus IFNβ vaccination protocol might confer survival benefit. (Clinical trial registration number: UMIN 000012146).  相似文献   
973.
Odontology - Different types of brackets seem to influence the disruption of the oral microbial environment. Therefore, the aim of this study was to evaluate the influence of self-ligating brackets...  相似文献   
974.
975.
976.
977.
Odontology - This study was designed to investigate the effects of Sake Lees extracts (SLE, Sake Kasu) on the functional activity of odontoblastic cells and tooth pulp of the rats. For in vitro...  相似文献   
978.
979.
980.
International Journal of Clinical Oncology - The prognostic factors of retroperitoneal soft tissue sarcoma (STS) have been explored but not yet certain. This study evaluated the prognostic impact...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号